Characterization of Hepatocellular Carcinoma Patients with <b><i>FGF19</i></b> Amplification Assessed by Fluorescence in situ Hybridization: A Large Cohort Study
Author(s) -
Hyo Jeong Kang,
Farhan Haq,
Chang Ohk Sung,
Jene Choi,
SeungMo Hong,
SooHeang Eo,
Hui Jeong Jeong,
Jin-Ho Shin,
Ju Hyun Shim,
Han Chu Lee,
Jihyun An,
MiJu Kim,
Kyupyo Kim,
SungMin Ahn,
Eunsil Yu
Publication year - 2018
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 2235-1795
pISSN - 1664-5553
DOI - 10.1159/000488541
Subject(s) - fgf19 , fluorescence in situ hybridization , hepatocellular carcinoma , in situ hybridization , immunohistochemistry , medicine , hepatitis b virus , cancer research , pathology , biology , oncology , gene , gene expression , immunology , fibroblast growth factor , virus , receptor , genetics , chromosome
FGF19 amplification is a relatively novel type of genetic aberration that has been proposed to be a driver of hepatocarcinogenesis. Selective inhibitors of FGFR4 , a receptor of FGF19 , have been developed as targeted therapies for hepatocellular carcinoma (HCC). Despite the role of FGF19 in mediating HCC progression, the clinicopathological characterization of patients exhibiting FGF19 amplification remains unclear. Immunohistochemical staining is the simplest and most widely used method of identifying aberrations in the FGF19 gene, although its specificity is very low.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom